CSIMarket



Eli Lilly And Company  (LLY)
Other Ticker:  
 
 

LLY's Capital Expenditures Growth by Quarter and Year

Eli Lilly And's Capital Expenditures results by quarter and year




LLY Capital Expenditures (in millions $) FY 2022 FY 2021 FY 2020 FY 2019
IV Quarter December - 291.40 454.70 326.50
III Quarter September - 336.80 393.10 263.40
II Quarter June - 381.30 281.80 240.30
I Quarter March 365.40 300.30 258.30 203.70
FY   365.40 1,309.80 1,387.90 1,033.90



LLY Capital Expenditures first quarter 2022 Y/Y Growth Comment
Eli Lilly And Company achieved in the first quarter 2022, above Company average Capital Expenditures growth of 21.68% year on year, to $ 365.40 millions.

Looking into first quarter 2022 results within Major Pharmaceutical Preparations industry 95 other companies have achieved higher Capital Expenditures growth. While Eli Lilly And Company' s Capital Expenditures rise of 21.68% ranks overall at the positon no. 1610 in the first quarter 2022.




LLY Capital Expenditures ( Y/Y Growth %) 2022
2021 2020 2019
IV Quarter December - -35.91 % 39.26 % -17.2 %
III Quarter September - -14.32 % 49.24 % -2.37 %
II Quarter June - 35.31 % 17.27 % -22.48 %
I Quarter March 21.68 % 16.26 % 26.8 % -13.87 %
FY   - -5.63 % 34.24 % -14.6 %

Financial Statements
Eli Lilly And's first quarter 2022 Capital Expenditures $ 365.40 millions LLY's Income Statement
Eli Lilly And's first quarter 2021 Capital Expenditures $ 300.30 millions Quarterly LLY's Income Statement
New: More LLY's historic Capital Expenditures Growth >>


LLY Capital Expenditures (Quarter on Quarter Growth %)

2022
2021 2020 2019
IV Quarter December - -13.48 % 15.67 % 23.96 %
III Quarter September - -11.67 % 39.5 % 9.61 %
II Quarter June - 26.97 % 9.1 % 17.97 %
I Quarter March 25.39 % -33.96 % -20.89 % -48.34 %
FY (Year on Year)   - -5.63 % 34.24 % -14.6 %




Capital Expenditures first quarter 2022 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #96
Healthcare Sector #302
Overall #1610

Capital Expenditures Y/Y Growth Statistics
High Average Low
131.05 % 4.9 % -66.84 %
(Sep 30 2015)   (Sep 30 2016)
Capital Expenditures first quarter 2022 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #96
Healthcare Sector #302
Overall #1610
Capital Expenditures Y/Y Growth Statistics
High Average Low
131.05 % 4.9 % -66.84 %
(Sep 30 2015)   (Sep 30 2016)

Capital Expenditures by Quarter for the Fiscal Years 2019, 2020, 2021, 2022

Eli Lilly And's Q/Q Capital Expenditures Growth


Capital Expenditures Q/Q Growth Statistics
High Average Low
206.39 % 22.29 % -85.4 %
(Sep 30 2015)   (March 31. 2011)


LLY's I. Quarter Q/Q Capital Expenditures Comment
Eli Lilly And Company achieved in the I. Quarter 2022 above company average sequential Capital Expenditures jump of 25.39%, to $ 365.40 millions, from $291.40 millions in the forth quarter.
LLY is undergoing a remarkable growth, not just recording above regular gain, but also increasing rate, Brian Walker, Major Pharmaceutical Preparations industry insider added.

Within Major Pharmaceutical Preparations industry 69 other companies have achieved higher Capital Expenditures quarter on quarter growth. While Eli Lilly And's Capital Expenditures growth quarter on quarter, overall rank is 701.


Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #70
Healthcare Sector #177
Overall #701
Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #70
Healthcare Sector #177
Overall #701
Capital Expenditures Q/Q Growth Statistics
High Average Low
206.39 % 22.29 % -85.4 %
(Sep 30 2015)   (March 31. 2011)


LLY's I. Quarter Q/Q Capital Expenditures Comment
Eli Lilly And Company achieved in the I. Quarter 2022 above company average sequential Capital Expenditures jump of 25.39%, to $ 365.40 millions, from $291.40 millions in the forth quarter.
LLY is undergoing a remarkable growth, not just claiming better then average growth, but also improving speed, Brian Walker, Major Pharmaceutical Preparations industry insider said.

Within Major Pharmaceutical Preparations industry 69 other companies have achieved higher Capital Expenditures quarter on quarter growth. While Eli Lilly And's Capital Expenditures growth quarter on quarter, overall rank is 701.


Eli Lilly And's 12 Months Capital Expenditures Growth Year on Year


Capital Expenditures TTM Growth

12 Months Ending
(Mar 31 2022)
12 Months Ending
(Dec 31 2021)
12 Months Ending
(Sep 30 2021)
12 Months Ending
(Jun 30 2021)
12 Months Ending
(Mar 31 2021)
Cumulative Capital Expenditures 12 Months Ending $ 1,374.90 $ 1,309.80 $ 1,473.10 $ 1,529.40 $ 1,429.90
Y / Y Capital Expenditures Growth (TTM) -3.85 % -5.63 % 16.94 % 35.35 % 31.36 %
Year on Year Capital Expenditures Growth Overall Ranking # 905 # 1670 # 1160 # 746 # 695
Seqeuential Capital Expenditures Change (TTM) 4.97 % -11.09 % -3.68 % 6.96 % 3.03 %
Seq. Capital Expenditures Growth (TTM) Overall Ranking # 654 # 2108 # 2289 # 1382 # 1133




Cumulative Capital Expenditures growth Comment
Eli Lilly And showed decline, but improvement compare to trailing twelve month Capital Expenditures decrease in Dec 31 2021. If the fiscal year would end in Mar 31 2022, Eli Lilly And's annual Capital Expenditures improvement would be -3.85% year on year to $1,375 millions.

In the Healthcare sector 114 other companies have achieved higher trailing twelve month Capital Expenditures growth. While Total ranking has impoved so far to 905, from total ranking in previous quarter at 1670.

Capital Expenditures TTM Q/Q Growth Statistics
High Average Low
1495.62 %
42.08 %
-80.2 %
 

Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 17
Healthcare Sector # 115
Overall # 905

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
1955.54 %
73.9 %
-86.89 %
 


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry # 17
Sector # 81
S&P 500 # 654
Cumulative Capital Expenditures growth Comment
Eli Lilly And showed decline, but improvement compare to trailing twelve month Capital Expenditures decrease in Dec 31 2021. If the fiscal year would end in Mar 31 2022, Eli Lilly And's annual Capital Expenditures drop would be -3.85% year on year to $1,375 millions.

In the Healthcare sector 114 other companies have achieved higher trailing twelve month Capital Expenditures growth. While Total ranking has impoved so far to 905, from total ranking in previous quarter at 1670.

Capital Expenditures TTM Q/Q Growth Statistics
High Average Low
1495.62 %
42.08 %
-80.2 %
 


Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 17
Healthcare Sector # 115
Overall # 905

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
1955.54 %
73.9 %
-86.89 %
 


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry # 17
Sector # 81
S&P 500 # 654




Other Capital Expenditures Growth
Major Pharmaceutical Preparations Industry Capital Expenditures Growth Trends and Statistics
Healthcare Sector Capital Expenditures Growth Statistics
Capital Expenditures Growth Trends for overall market
LLY's Capital Expenditures Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Capital Expenditures Growth
Lowest Ranking Capital Expenditures Growth
Capital Expenditures Growth for LLY's Competitors
Capital Expenditures Growth for Eli Lilly And's Suppliers
Capital Expenditures Growth for LLY's Customers

You may also want to know
LLY's Annual Growth Rates LLY's Profitability Ratios LLY's Asset Turnover Ratio LLY's Dividend Growth
LLY's Roe LLY's Valuation Ratios LLY's Financial Strength Ratios LLY's Dividend Payout Ratio
LLY's Roa LLY's Inventory Turnover Ratio LLY's Growth Rates LLY's Dividend Comparisons



Companies with similar Capital Expenditures drop for the quarter ending Mar 31 2022 within Healthcare SectorY/Y Change %Capital Expenditures for the quarter ending Mar 31 2022
Endo International Plc37.60%$ 37.602 millions
Henry Schein Inc 37.25%$ 37.253 millions
Sigilon Therapeutics Inc 36.90%$ 36.897 millions
Organogenesis Holdings Inc 34.60%$ 34.598 millions
Phibro Animal Health Corp33.75%$ 33.747 millions
Vapotherm Inc 33.33%$ 33.333 millions
Lhc Group Inc32.85%$ 32.852 millions
Zimmer Biomet Holdings Inc 32.85%$ 32.847 millions
Heron Therapeutics Inc 32.82%$ 32.824 millions
Signify Health Inc 32.81%$ 32.813 millions
Tcr2 Therapeutics Inc 32.60%$ 32.596 millions
Irhythm Technologies Inc 32.32%$ 32.320 millions
Medavail Holdings Inc 31.92%$ 31.923 millions
Hca Healthcare Inc 31.65%$ 31.651 millions
Vericel Corporation31.50%$ 31.498 millions
Viatris Inc 30.30%$ 30.303 millions
Sorrento Therapeutics Inc 30.04%$ 30.040 millions
1life Healthcare Inc 29.83%$ 29.828 millions
Infusystem Holdings Inc28.99%$ 28.986 millions
Novocure Limited27.93%$ 27.933 millions
Heska Corporation27.48%$ 27.481 millions
United Therapeutics Corporation27.36%$ 27.358 millions
Molecular Templates Inc 27.13%$ 27.126 millions
Lannett Company Inc27.01%$ 27.005 millions
Diversified Healthcare Trust26.78%$ 26.783 millions
Lantheus Holdings Inc 26.59%$ 26.587 millions
Nuvasive Inc26.47%$ 26.467 millions
Surgery Partners Inc 25.52%$ 25.517 millions
Akoya Biosciences Inc 25.47%$ 25.469 millions
Nuwellis Inc 25.00%$ 25.000 millions


       
Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

PPCH's Profile

Stock Price

PPCH's Financials

Business Description

Fundamentals

Charts & Quotes

PPCH's News

Suppliers

PPCH's Competitors

Customers & Markets

Economic Indicators

PPCH's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Cryptocurrencies

Sectors & Industries

Commodities

Currencies

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.    Copyright © 2022 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071